Unsurprisingly, MHC-I expression or other antigen presentation machinery, which is indispensable for CD8+ T cell-mediated tumor-cell killing, is frequently dysregulated or lost in various cancer types, resulting in resistance to ICB [93–96]. This evidence concerns the gene CD8A and cancer.